Abstract:The stable activation of the WNT signaling effector beta-catenin (CTNNB1(ex3)) in ovarian granulosa cells results in the formation of premalignant lesions that develop into granulosa cell tumors (GCTs) spontaneously later in life. Although loss of the tumor suppressor gene Pten alone rarely leads to GCTs, its disruption in granulosa cells that concomitantly express a dominant-stable CTNNB1 mutant accelerates tumor formation. Expression of mutant (oncogenic) KRASG12D in granulosa cells results in the arrest of proliferation, differentiation and apoptosis. In this study, we sought to determine if KRAS activation would retard or block the ovarian phenotype of mice expressing dominant-stable CTNNB1. Unexpectedly, transgenic mice bearing mutations of CTNNB1 and KRAS developed early-onset GCTs leading to premature death in a manner similar to the Ctnnb1;Pten mutant mice. GCT cells in these animals were characterized by increased rates of proliferation, decreased apoptosis and reduced expression of markers of granulosa cell differentiation relative to normal ovaries. Microarray and RT-PCR studies were performed comparing control ovaries, ovaries from mice expressing dominant-stable CTNNB1, and ovaries bearing early-stage tumors from mice with the CTNNB1 mutation and either Pten loss or KRAS activation. Results demonstrated that gene regulatory processes induced by CTNNB1 were mostly further enhanced by either KRAS activation or Pten loss, and that the latter mutations largely affected the expression of the same genes in remarkably similar patterns. Granulosa cells from the tumors proliferate in culture and retain expression of selected CTNNB1 target genes. In addition, concomitant activation of CTNNB1 and KRAS in Sertoli cells resulted in the development of granulosa cell tumors of the testis similar to those observed in the Ctnnb1;Pten mutant mice. Real time-PCR studies showed a partial overlap in gene regulatory processes associated with tumor development in the ovarian and testicular GCTs. Collectively, these results suggest that mutant stable CTNNB1 alters the granulosa cell genetic program and predisposes these cells to transformation whereby either KRAS activation or Pten loss induce GCT development from premalignant lesions via highly similar molecular mechanisms. Supported in part by NIH-HD-16229 and HD-07945 (J.S.R.) and the Canadian Institutes of Health Research (D.B.). (poster)

Supplementary Methods, Table, Figures 1-4 from Cell Type–Specific Targeted Mutations of <i>Kras</i> and <i>Pten</i> Document Proliferation Arrest in Granulosa Cells versus Oncogenic Insult to Ovarian Surface Epithelial Cells

Supplementary Methods, Table, Figures 1-4 from Cell Type–Specific Targeted Mutations of <i>kras</i> and <i>pten</i> Document Proliferation Arrest in Granulosa Cells Versus Oncogenic Insult to Ovarian Surface Epithelial Cells

Cell Type-Specific Targeted Mutations of Kras and Pten Document Proliferation Arrest in Granulosa Cells Versus Oncogenic Insult to Ovarian Surface Epithelial Cells.

Either Kras Activation or Pten Loss Similarly Enhance the Mutant CTNNB1-Induced Genetic Program to Promote Granulosa Cell Tumor Development in Ovary and Testis.

Supplementary Tables 1-2 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Information from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Either Kras Activation or Pten Loss Similarly Enhance the Dominant-Stable CTNNB1-induced Genetic Program to Promote Granulosa Cell Tumor Development in the Ovary and Testis

Supplementary Material and Methods from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Figures 1-4 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Molecular and Functional Characteristics of Ovarian Surface Epithelial Cells Transformed by Krasg12d and Loss of Pten in A Mouse Model in Vivo

Selective Expression Of Kras(G12d) In Granulosa Cells Of The Mouse Ovary Causes Defects In Follicle Development And Ovulation

Supplementary Figure Legends 1- 4 from PTEN Loss Accelerates <i>Kras</i><sup><i>G12D</i></sup>-Induced Pancreatic Cancer Development

Supplementary Table 3 from <i>Pten</i> Inactivation Accelerates Oncogenic <i>K-ras</i>–Initiated Tumorigenesis in a Mouse Model of Lung Cancer

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Figure 4 from PTEN Loss Accelerates <i>Kras</i><sup><i>G12D</i></sup>-Induced Pancreatic Cancer Development

Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer

Supplementary Methods and Table from Frequent <i>Met</i> Oncogene Amplification in a <i>Brca1/Trp53</i> Mouse Model of Mammary Tumorigenesis

Supplementary Figure 1 from PTEN Loss Accelerates <i>Kras</i><sup><i>G12D</i></sup>-Induced Pancreatic Cancer Development

Supplementary Methods and Data (posted 7/5/2011) from Characterization of <i>KRAS</i> Rearrangements in Metastatic Prostate Cancer

Supplementary Methods, Table, Figures 1-4 from Cell Type–Specific Targeted Mutations of &lt;i&gt;Kras&lt;/i&gt; and &lt;i&gt;Pten&lt;/i&gt; Document Proliferation Arrest in Granulosa Cells versus Oncogenic Insult to Ovarian Surface Epithelial Cells

Supplementary Methods, Table, Figures 1-4 from Cell Type–Specific Targeted Mutations of &lt;i&gt;kras&lt;/i&gt; and &lt;i&gt;pten&lt;/i&gt; Document Proliferation Arrest in Granulosa Cells Versus Oncogenic Insult to Ovarian Surface Epithelial Cells